Literature DB >> 8889058

IgG subclass antibodies to human cytomegalovirus (CMV) in normal human plasma samples and immune globulins and their neutralizing activities.

C K Gupta1, J Leszczynski, R K Gupta, G R Siber.   

Abstract

An enzyme-linked immunoabsorbent assay (ELISA) was developed for quantitation of IgG subclass antibodies to human cytomegalovirus (CMV) in human serum or plasma samples and in immune globulin (IG) preparations. The assay was based on the parallel titration of known concentrations of purified IgG subclass myeloma proteins and a specific CMV antiserum. The purified IgG subclass myeloma proteins were captured on an ELISA plate pre-coated with anti-human kappa, anti-human lambda or a mixture of anti-human kappa and lambda antibodies and the specific antiserum was titrated against CMV antigen coated on the plate. IgG subclass antibodies, captured or bound to antigen, were quantitated with IGG subclass heavy chain specific monoclonal antibodies. The method was highly reproducible, specific and sensitive. Using this method, 257 human plasma samples and 50 IG preparations were assayed for CMV specific IgG subclass and IgM antibodies. The major IgG subclass antibody to CMV was IgG1 which represented more than 96% of CMV IgG antibodies, followed by IgG3 (mean CMV IgG3 antibody content was 3% of IgG antibodies in IG preparations and 1.8% in plasma samples). A majority of the samples had low levels of IgG2 antibodies and a few samples exhibited low levels of IgG4 antibodies. IG preparations showed very low levels of CMV IgM antibodies whereas plasma samples had 14.2% of CMV antibodies (IgG and IgM) as IgM antibodies. Virus neutralizing (Nt) activity of these samples showed a significant correlation with CMV IgG1 antibodies. Nine samples of plasma and IGs were further evaluated for Nt activity of IgG1 and IgG3 antibodies by separating IgG3 from the rest of the antibodies with protein A agarose. IgG3 antibodies showed much higher Nt activity than IgG1 antibodies suggesting that enrichment of IgG3 antibodies in IG preparations may be useful in preparing CMV specific IG.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8889058     DOI: 10.1006/biol.1996.0015

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  8 in total

1.  Impaired gamma interferon responses against parvovirus B19 by recently infected children.

Authors:  A Corcoran; S Doyle; D Waldron; A Nicholson; B P Mahon
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Comparison of immunoglobulin G subclass profiles induced by measles virus in vaccinated and naturally infected individuals.

Authors:  María Beatríz Isa; Laura Martínez; Miguel Giordano; Carlos Passeggi; María Cristina de Wolff; Silvia Nates
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

3.  Measles virus-specific immunoglobulin G isotype immune response in early and late infections.

Authors:  M B Isa; L Martínez; M Giordano; M Zapata; C Passeggi; M C De Wolff; S Nates
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

Review 4.  CMV-encoded Fcγ receptors: modulators at the interface of innate and adaptive immunity.

Authors:  Eugenia Corrales-Aguilar; Katja Hoffmann; Hartmut Hengel
Journal:  Semin Immunopathol       Date:  2014-10-07       Impact factor: 9.623

5.  Heterosubtypic anti-avian H5N1 influenza antibodies in intravenous immunoglobulins from globally separate populations protect against H5N1 infection in cell culture.

Authors:  John S Sullivan; Paul W Selleck; Teena Downton; Ingrid Boehm; Anna-Maree Axell; Yasmin Ayob; Natalie M Kapitza; Wayne Dyer; Anna Fitzgerald; Bradley Walsh; Garry W Lynch
Journal:  J Mol Genet Med       Date:  2009-12-23

6.  HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions.

Authors:  Cody S Nelson; Tori Huffman; Jennifer A Jenks; Eduardo Cisneros de la Rosa; Guanhua Xie; Nathan Vandergrift; Robert F Pass; Justin Pollara; Sallie R Permar
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-30       Impact factor: 12.779

7.  Human cytomegalovirus Fcγ binding proteins gp34 and gp68 antagonize Fcγ receptors I, II and III.

Authors:  Eugenia Corrales-Aguilar; Mirko Trilling; Katja Hunold; Manuela Fiedler; Vu Thuy Khanh Le; Henrike Reinhard; Katrin Ehrhardt; Eva Mercé-Maldonado; Enver Aliyev; Albert Zimmermann; David C Johnson; Hartmut Hengel
Journal:  PLoS Pathog       Date:  2014-05-15       Impact factor: 6.823

8.  Sudan ebolavirus long recovered survivors produce GP-specific Abs that are of the IgG1 subclass and preferentially bind FcγRI.

Authors:  Olga Radinsky; Avishay Edri; Michael Brusilovsky; Shlomit Fedida-Metula; Ariel Sobarzo; Orly Gershoni-Yahalom; Julius Lutwama; John Dye; Leslie Lobel; Angel Porgador
Journal:  Sci Rep       Date:  2017-07-20       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.